

JOSH SHIN

Partner
Fangda Partners

+86 21 2208 1109
jshin@fangdalaw.com



PRACTICE AREAS

MR. JOSH SHIN SPECIALIZES IN CORPORATE AND COMMERCIAL LAW MATTERS. HE HAS MAINTAINED A BALANCED PRACTICE STYLE BETWEEN TRANSACTION AND REGULATORY MATTERS, WITH A CONVINCING TRACK RECORD IN VARIOUS INDUSTRY SECTORS SUCH AS PHARMA, LIFE SCIENCE, PRIVATE EDUCATION AND GENERAL INDUSTRIES SECTORS.

REPRESENTATIVE MATTERS AND CASES

Mergers and Acquisitions/Equity Financing:

- Representing Redwood China Logistics Fund and other sellers in the sale of top tier logistics assets in PRC mainland to the entity established by ESR and Manulife Financial Group
- Representing Eddingpharm on its acquisition from Eli Lilly of the rights for two legacy antibiotic medicines in China: Ceclor and Vancocin, as well as a manufacturing facility in Suzhou
- Representing Bayer Healthcare China in selling its TCM products and manufacturing plant to a leading China pharmaceutical company
- Representing Everbright Holdings in its investment in Shenzhen Lifetech (01302.HK), the leading supplier of minimally invasive interventional medical devices to treat cardiovascular diseases
- Representing Covestro AG in its proposed acquisition of a leading thin film company in Guangdong Province
- Representing EddingPharm in its restructuring and Series E/F financings
- Representing E-Shang Redwood in its series acquisitions/disposals of 30+ logistic assets in China

- Representing Ping'An, ARA, LOGOS, and Sun Jade Capital in its series acquisitions of logistic assets in China
- Representing MitrAssist (a leading clinical stage medical devices company offering innovative treatment to Mitral Regurgitation) in restructuring, acquisition and Series A/B/C financing
- Representing AnHeart Therapeutics in its cross-border restructuring and Series A+/A-2/B equity financing
- Representing Bayer HealthCare China in reorganization its corporate structure for integration with the onshore part of Merck OTC Business, following Bayer's global acquisition of Merck OTC department
- Representing Bayer AG in its acquisition of 100% interest in Dihon Pharmaceutical Group, a leading OTC and traditional Chinese medicine company in China
- Representing Wuxi AppTec in forming a joint venture with Mayo Clinics regarding advanced medical examination technologies
- Representing Education Index Management (the owner of Dulwich College International) in its various rounds private equity financing
- Advising British Education (running Wycombe Abby China schools) in its private equity financing as well as operational matters
- Representing a USD fund in its proposed investment in NIT Education
- Representing World Strides, the largest educational travel company in the world, in acquiring summer camping business in China
- Representing Parkway Health, a leading healthcare services provider in Asia in its investment into several private hospitals and clinics in various provinces in China
- Representing PAG, in its proposed acquisition of Cardinal Health's China business
- Representing Mount Kellett (now Fortress Investment) in its series equity investments in China

Product License/Collaboration:

- Representing CStone Pharmaceuticals in granting the exclusive rights to Hengrui Pharmaceuticals for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
- Representing I-Mab BioPharma in reaching a co-promotion arrangement with Fosun Pharmaceuticals regarding one of its core products

- Representing OnCusp Therapeutics in obtaining global (ex-China) exclusive license to METTL-3 therapy from a leading research based life-sciences company
- Representing Galixir (empowering drug discovering with its AI based platform) in its various license-in transactions and pipeline establishment
- Representing Anheart Therapeutics, in granting exclusive commercialization right in PRC market with respect to Anheart's lead drug candidate taletrectinib, a next-generation tyrosine kinase inhibitor (TKI) designed to effectively target ROS1 and NTRK to Innovent
- Representing medical devices companies including Baxter and Cordis, in connection with its contract design, contract R&D and contract manufacturing transaction in China market
- Representing AstraZeneca in obtaining exclusive commercialization rights in PRC market with respect to certain drug products treating hyperkalemia from a leading Japan pharmaceutical company
- Representing Diurnal Group (an UK based innovative pharmaceutical company) in granting exclusive license in PRC market with respect to certain drug product to a clinical stage domestic pharma company
- Representing F-Star (an UK based innovative pharmaceutical company) in granting exclusive license in PRC market with respect to a rare disease drug to Citrine
- Representing MitrAssist in obtaining licenses of technologies relating to MR treatment from various licensors
- Representing Tibet Rhodiola (known as Tibet Pharmaceuticals) in obtaining certain rights with respect to Sputnik-V, an adenovirus vector-based COVID-19 vaccine from Russia Direct Investment Fund (belongs to Russia Sovereign)
- Representing AstraZeneca in granting to BioKangtai the exclusive license in China with respect to the AZD1222, an adenovirus vector-based COVID-19 vaccine initially developed by Oxford University
- Representing C-Stone Pharmaceuticals in its obtaining of global license from WuXi Biologics relating to PD-L1/TGFβ bifunctional molecule
- Represented C-Stone Pharmaceuticals in its collaboration with Zelgen with respect to combined therapy study of compounds from two parties
- Representing Harbour BioMed in its collaboration with Kelun-Biotech to develop fully human therapeutic monoclonal antibodies based on Harbour's patented H2L2 transgenic mouse platform

- Representing AstraZeneca in obtaining the exclusive promotion rights Luye Pharmaceuticals with respect to Xue Zhi Kang Capsule, a first-line blood lipid management drug. This is the first time that a multinational pharmaceutical company has gained exclusive authorization in China to promote an innovative drug independently developed by a Chinese pharmaceutical company
- Representing AstraZeneca in its granting of certain rights in China relating to a key originator drug to a leading domestic pharma company
- Representing Novartis in its granting of exclusive promotion rights in China in relation to certain respiratory drugs to a leading domestic pharma company
- Representing AstraZeneca in its granting of exclusive commercialization rights to Plendil in China market to China Medical System for an upfront fee of USD310million and ongoing economic sharing
- Representing AstraZeneca in its granting of exclusive commercialization rights to certain GLP-1 diabetes drugs in China market to 3Sbio for an upfront fee of USD100million and ongoing economic sharing

General Corporate/Regulatory Works:

- Representing Covestro AG, E-Shang Redwood, Education Index, Celanese and a number of other companies, in regulatory issues arising from daily business
- Representing Johnson Matthey in various daily operational and compliance matters
- Advising Dulwich College International China schools and Dehong Chinese International School various legal issues in daily operation, including new school opening, campus construction/expansion, regulatory compliance, related party transaction, procurement, data protection, school management, debt financing, etc
- Advising partners of Alibaba in establishing Yungu School
- Advising Shanghai Concord Bilingual School in its corporate restructuring, campus expansion and daily operation
- Representing life sciences companies including ASPEN, AnHeart Therapeutics, Smith Nephew, Novartis AG, Roche Pharmaceuticals, AstraZeneca, Vazyme Biotech, Astellas Pharma, C-Stone Pharmaceuticals, Zai Lab, Biogen, Laekna Therapeutics, Assembly BioSciences, Bayer Healthcare, Visen Pharmaceuticals and Karl Zeiss, in regulatory issues arising from daily business, including research and development projects, clinical trials, market authorization, product distribution, PAP/PSP, PBM, product promotion, and NGO/PAG interactions, and acting as de facto GC

for some of those companies

Capital Markets:

- Advising issuers/underwriters in a number of bond offering transactions, including GCL Poly, Biostime, Asia Standard, et
- Advising issuers/underwriters in a number of initial public offerings and other capital market transactions, including IPO of EddingPharm at HKSE (A-1 submission), follow-on offering of Chi-Med at NASDAQ, IPO of C-Stone Pharmaceuticals at HKSE, IPO of Zai Lab at NASDAQ, IPO of Wuxi Biologics at HKSE, IPO of Simcom at HKSE, IPO of Ruici Health at HKSE, IPO and follow-up offerings of Trina Solar at NASDAQ, IPO of Montage Technology at NASDAQ, IPO of ShangPharma at NYSE, IPO of China iKang at NYSE, etc
- Representing the buyers group led by the founder and TPG in its taking private of ShangPharma Corporation, a leading China-based CRO company
- Representing the buyers group led by the founder in its attempted taking private of iKang Healthcare Group Inc.

OTHER INFORMATION

Education

- University College London (UCL), Faculty of Law, LL.M
- Fudan University, School of Law, LL.B

Professional Qualification

- Admitted to practice in the PRC

Presentations/Speeches

- Panel speaker “Regulatory Updates from China and Abroad”, China Cross-Border M&A and Private Equity Investment Forum (2020 Shanghai)
- Panel speaker “Deal Drivers in Healthcare and Life Sciences: Mainland China” by Merger Market (2020 Webinar)
- Panel speaker “From Clinics to Sales – the Pathway and Challenge of Commercialization of Innovative Life Science Company” Wuxi AppTec Healthcare Forum (2019 Shanghai)
- Panel speaker “New Competition Dynamic Brought by Medical Reform” AstraZeneca Annual Conference (2018 Chengdu)
- Keynote Speaker “Recent Regulatory Development in Pharmaceutical

Distribution” CCPIT Compliance Conference (2018 Shanghai)

- Panel speaker “Compliance Hot Issues in Pharma Area” CCPIT Compliance Conference (2018 Beijing)
- Panel speaker “Recent Trend in Healthcare M&A” IBA Hong Kong Asia Pacific M&A Conference (2017 Hong Kong)

Publications

- Lead Author “Pharma Legal Handbook - PRC” published by Pharma Boardroom (edition 2019 and 2021).

Honors and Awards

- Recommended as ranked lawyer for healthcare by Chambers and Partners – Asia Pacific 2019 - 2022
- Recommended as leading individual for “healthcare and life-science” by Legal 500 –Asia Pacific 2020 - 2022
- Pharmaceutical, Medical and Biotech M&A Legal Advisor of the Year 2019, by Merger Market